• Edmund Chiong, Miah Hiang Tay, Min Han Tan, Santosh Kumar, Hong Gee Sim, Bin Tean Teh, Rainy Umbas, and Noan Minh Chau.
• Department of Urology, National University Health System, Singapore. surce@nus.edu.sg
• Lancet Oncol.. 2012 Nov 1;13(11):e482-91.

AbstractTreatment of renal-cell carcinoma has progressed over the past decade, in terms of surgical and systemic therapy. Current treatment guidelines are based on clinical evidence, but do not take into account resource limitations among different countries. These limitations, which include financial and logistical challenges and lack of skilled health-care professionals, have the greatest effect in low-income countries. This consolidated statement gives treatment recommendations for renal-cell carcinoma that are based on clinical evidence and stratified according to extent of resource availability. The statement was formulated by a panel of urologists, medical oncologists, and clinical oncologists from Asian countries, at a consensus session on kidney cancer that was held as part of the 2012 Asian Oncology Summit in Singapore. Resource levels are defined according to a four-tier system (basic, limited, enhanced, and maximum), and treatment recommendations are specified based on availability of financial, skill, and logistical resources.Copyright © 2012 Elsevier Ltd. All rights reserved.

21 keywords...

hide…